Literature DB >> 35023092

Genotypic and Clinical Analysis of a Thalassemia Major Cohort: An Observational Study.

Tsartsalis A1, George I Lambrou2, Athanasia Samartzi3, Eugenia Vlachou4, Ioannis Papassotiriou5, Styliani A Geronikolou6, Christina Kanaka-Gantenbein7, George P Chrousos2, Antonis Kattamis8.   

Abstract

Thalassemia major (TM) is a hereditary disease caused by defective globin synthesis. Because of the significant increase in life expectancy, these patients are suffering from various health conditions, including endocrinopathies and low bone mineral density. The aim of the present study was to investigate the correlation between clinical and biochemical parameters as well as to identify possible relations in a genotype to phenotype pattern. Sixty-four patients with TM (32 men and 32 women) participated in a cross-sectional study design. The patients were recruited from "Aghia Sofia" Children's Hospital. Clinical and biochemical parameters were evaluated as well as specific mutations were identified. We have found significant correlations between biochemical parameters and iron chelation, hormone replacement treatment as well as TM genotype and hematocrit and T-score. To conclude, the current study showed that clinical parameters of TM patients correlate significantly with both biochemical factors and genotypical patient parameters. Our present study showed that there is a connection between genotype and phenotype as, for example, the identified relation between hematocrit and T-scores and TM-specific mutations. This connection indicates that there is still much more to learn about the role of mutations not only in the disease itself but also in the underlying comorbidities.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Biochemical parameters; Mutation frequency; T-score; Thalassemia

Mesh:

Year:  2021        PMID: 35023092     DOI: 10.1007/978-3-030-78787-5_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  22 in total

Review 1.  Genetic disorders of hemoglobin.

Authors:  D J Weatherall; J B Clegg
Journal:  Semin Hematol       Date:  1999-10       Impact factor: 3.851

Review 2.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

3.  A newly discovered human alpha-globin gene.

Authors:  Sung-Ho Goh; Y Terry Lee; Natarajan V Bhanu; Margaret C Cam; Richard Desper; Brian M Martin; Ramy Moharram; Robert B Gherman; Jeffery L Miller
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

4.  Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

Authors:  Zaher K Otrock; Sami T Azar; Wael A Shamseddeen; Dany Habr; Adlette Inati; Suzane Koussa; Rami A R Mahfouz; Ali T Taher
Journal:  Ann Hematol       Date:  2006-07-08       Impact factor: 3.673

5.  Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis.

Authors:  Ersi Voskaridou; Eleni Stoupa; Lito Antoniadou; Evangelos Premetis; Kostas Konstantopoulos; Ioannis Papassotiriou; Evangelos Terpos
Journal:  Haematologica       Date:  2006-05-16       Impact factor: 9.941

6.  Bone mineral metabolism in adults with beta-thalassaemia major and intermedia.

Authors:  R Dresner Pollack; E Rachmilewitz; A Blumenfeld; M Idelson; A W Goldfarb
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

7.  Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study.

Authors:  Athanasios N Tsartsalis; George I Lambrou; Dimitrios N Tsartsalis; Ioannis Papassotiriou; Eugenia Vlachou; Evaggelos Terpos; George P Chrousos; Christina Kanaka-Gantenbein; Antonis Kattamis
Journal:  Curr Mol Med       Date:  2019       Impact factor: 2.222

8.  The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.

Authors:  Jordan M Spatz; Marc N Wein; Jonathan H Gooi; Yili Qu; Jenna L Garr; Shawn Liu; Kevin J Barry; Yuhei Uda; Forest Lai; Christopher Dedic; Mercedes Balcells-Camps; Henry M Kronenberg; Philip Babij; Paola Divieti Pajevic
Journal:  J Biol Chem       Date:  2015-05-07       Impact factor: 5.157

Review 9.  Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy: a study by the Korean Red Blood Cell Disorder Working Party of the Korean Society of Hematology.

Authors:  Young Kyung Lee; Hee-Jin Kim; Kyunghoon Lee; Sang Hyuk Park; Sang Hoon Song; Moon-Woo Seong; Myungshin Kim; Jin Yeong Han
Journal:  Blood Res       Date:  2019-03-21

10.  Gene Therapy For Beta-Thalassemia: Updated Perspectives.

Authors:  Garyfalia Karponi; Nikolaos Zogas
Journal:  Appl Clin Genet       Date:  2019-09-23
View more
  1 in total

Review 1.  New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Authors:  Mara Carsote; Cristina Vasiliu; Alexandra Ioana Trandafir; Simona Elena Albu; Mihai-Cristian Dumitrascu; Adelina Popa; Claudia Mehedintu; Razvan-Cosmin Petca; Aida Petca; Florica Sandru
Journal:  Diagnostics (Basel)       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.